Wells Fargo’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-49,373
| Closed | -$150K | – | 7360 |
|
|
2024
Q4 | $150K | Buy |
49,373
+10,675
| +28% | +$46.5K | ﹤0.01% | 4963 |
|
|
2024
Q3 | $201K | Sell |
38,698
-24,232
| -39% | -$120K | ﹤0.01% | 4578 |
|
|
2024
Q2 | $162K | Buy |
62,930
+7,857
| +14% | +$26.8K | ﹤0.01% | 4646 |
|
|
2024
Q1 | $271K | Buy |
55,073
+16,794
| +44% | +$99.4K | ﹤0.01% | 4278 |
|
|
2023
Q4 | $336K | Buy |
38,279
+2,946
| +8% | +$24.1K | ﹤0.01% | 4137 |
|
|
2023
Q3 | $405K | Sell |
35,333
-36,674
| -51% | -$705K | ﹤0.01% | 3913 |
|
|
2023
Q2 | $1.82M | Buy |
72,007
+17,990
| +33% | +$560K | ﹤0.01% | 2989 |
|
|
2023
Q1 | $1.74M | Sell |
54,017
-30,220
| -36% | -$942K | ﹤0.01% | 2987 |
|
|
2022
Q4 | $1.56M | Sell |
84,237
-8,268
| -9% | -$189K | ﹤0.01% | 2960 |
|
|
2022
Q3 | $2.5M | Buy |
92,505
+168
| +0.2% | +$3.41K | ﹤0.01% | 2551 |
|
|
2022
Q2 | $1.28M | Sell |
92,337
-11,093
| -11% | -$171K | ﹤0.01% | 3129 |
|
|
2022
Q1 | $2.02M | Sell |
103,430
-66,809
| -39% | -$1.01M | ﹤0.01% | 3295 |
|
|
2021
Q4 | $2.78M | Sell |
170,239
-323,145
| -65% | -$5.39M | ﹤0.01% | 3165 |
|
|
2021
Q3 | $13.7M | Buy |
493,384
+86,375
| +21% | +$2.46M | ﹤0.01% | 1953 |
|
|
2021
Q2 | $12.1M | Sell |
407,009
-13,373
| -3% | -$386K | ﹤0.01% | 2079 |
|
|
2021
Q1 | $11.8M | Sell |
420,382
-9,418
| -2% | -$260K | ﹤0.01% | 2072 |
|
|
2020
Q4 | $12.2M | Buy |
429,800
+177,807
| +71% | +$4.61M | ﹤0.01% | 1936 |
|
|
2020
Q3 | $6.33M | Buy |
251,993
+174,266
| +224% | +$4.57M | ﹤0.01% | 2287 |
|
|
2020
Q2 | $1.9M | Buy |
77,727
+21,151
| +37% | +$417K | ﹤0.01% | 3300 |
|
|
2020
Q1 | $837K | Buy |
56,576
+11,674
| +26% | +$241K | ﹤0.01% | 3656 |
|
|
2019
Q4 | $728K | Buy |
44,902
+16,503
| +58% | +$256K | ﹤0.01% | 4080 |
|
|
2019
Q3 | $369K | Buy |
28,399
+1,718
| +6% | +$21K | ﹤0.01% | 4583 |
|
|
2019
Q2 | $346K | Buy |
26,681
+6,848
| +35% | +$86.3K | ﹤0.01% | 4636 |
|
|
2019
Q1 | $313K | Buy |
19,833
+1,654
| +9% | +$28.7K | ﹤0.01% | 4600 |
|
|
2018
Q4 | $366K | Buy |
18,179
+2,479
| +16% | +$54.6K | ﹤0.01% | 4534 |
|
|
2018
Q3 | $390K | Buy |
15,700
+1,218
| +8% | +$33.1K | ﹤0.01% | 4608 |
|
|
2018
Q2 | $398K | Sell |
14,482
-11,153
| -44% | -$335K | ﹤0.01% | 4627 |
|
|
2018
Q1 | $789K | Buy |
25,635
+11,695
| +84% | +$376K | ﹤0.01% | 4083 |
|
|
2017
Q4 | $499K | Sell |
13,940
-5,017
| -26% | -$144K | ﹤0.01% | 4399 |
|
|
2017
Q3 | $522K | Sell |
18,957
-4,327
| -19% | -$105K | ﹤0.01% | 4298 |
|
|
2017
Q2 | $615K | Sell |
23,284
-47,864
| -67% | -$1.07M | ﹤0.01% | 4081 |
|
|
2017
Q1 | $1.48M | Sell |
71,148
-14,632
| -17% | -$301K | ﹤0.01% | 3446 |
|
|
2016
Q4 | $1.78M | Buy |
85,780
+74,793
| +681% | +$1.25M | ﹤0.01% | 3250 |
|
|
2016
Q3 | $178K | Buy |
10,987
+1,759
| +19% | +$25.5K | ﹤0.01% | 4547 |
|
|
2016
Q2 | $126K | Sell |
9,228
-1,291
| -12% | -$22.8K | ﹤0.01% | 4679 |
|
|
2016
Q1 | $184K | Buy |
10,519
+3,126
| +42% | +$63.6K | ﹤0.01% | 4451 |
|
|
2015
Q4 | $253K | Sell |
7,393
-1,367
| -16% | -$47.4K | ﹤0.01% | 4314 |
|
|
2015
Q3 | $261K | Buy |
8,760
+1,442
| +20% | +$43.8K | ﹤0.01% | 4323 |
|
|
2015
Q2 | $234K | Buy |
7,318
+2,620
| +56% | +$67.4K | ﹤0.01% | 4526 |
|
|
2015
Q1 | $97K | Buy |
4,698
+2,851
| +154% | +$49.3K | ﹤0.01% | 4749 |
|
|
2014
Q4 | $32K | Buy |
1,847
+33
| +2% | +$576 | ﹤0.01% | 5188 |
|
|
2014
Q3 | $36K | Buy |
1,814
+676
| +59% | +$17.6K | ﹤0.01% | 5059 |
|
|
2014
Q2 | $39K | Buy |
+1,138
| New | +$35.7K | ﹤0.01% | 5069 |
|
Other funds holding RVNC
Wells Fargo's RVNC Position: Q1 2025 in Review
Wells Fargo sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 49,373 shares — an estimated $150K sold.
Wells Fargo first reported a position in RVNC in Q2 2014 and held it in 43 quarters. The position peaked at $13.7M in Q3 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Wells Fargo reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Wells Fargo sold 49,373 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $150K.
- Wells Fargo first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 43 quarters.
- Wells Fargo's Revance Therapeutics, Inc. position peaked at $13.7M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Wells Fargo's 13F filing for Q1 2025, filed 13 May 2025.